

PRELIMINARY PROGRAMME



Biofit

FOSTERING
INNOVATION
& TRANSFER

**The leading European partnering event
for early-stage innovations and seed
investment in the Life Sciences field**

**7th
edition**

**4th & 5th
Dec. 2018**

**LILLE
France**



THE ORGANISERS

EURASANTE

Eurasanté is an incubator, a technology transfer tool and a cluster manager all at once, in the biotech, medtech, nutrition and healthcare fields in Northern France. It helps French and foreign companies, entrepreneurs, scientists and clinicians with their innovations and development projects.

The regional network includes more than 1,000 companies working in the Life Sciences and Healthcare fields. It enjoys an exceptional location in the heart of Europe (near Paris, London, Brussels...). The Health field in the Hauts-de-France region features a combined total of 28,000 employees. Eurasanté also promotes the Eurasanté Bio-business Park which hosts 7 hospitals, 4 universities, 7 specialised schools, 170 companies and 50 laboratories.

In addition, Eurasanté organises 4 international partnering events, which aim to increase and improve interactions between academia and the industry.

www.eurasante.com @Eurasante



THE NHL CLUSTER

The Nutrition Health Longevity (NHL) Cluster is a dynamic network that is focused on the primary health issues of today, at the intersection of health, biotechnology and nutrition.

The NHL Cluster aims to connect academia and industry partners around R&D projects, leading to innovative products in the fields of nutrition and health.

The NHL Cluster focuses on the fields of prevention and treatment of lifestyle-related diseases, such as metabolic and cardiovascular pathologies, neurodegenerative diseases and inflammatory bowel diseases. Its goal is to gather and support players from the health and food sectors in designing, developing and financing their future products and processes.

www.nhl-cluster.com @PoleNSL



ALSACE BIOVALLEY

Alsace BioValley is a French competitiveness cluster which has for mission to federate, develop and promote health players through innovation. The priorities of the cluster are Medicine, Medical Technologies and e-Health.

Alsace BioValley actively participates in development projects of the health sector and supports its members in their R&D innovation approaches enabling them to access high national and international added-value expertise (regulatory, clinical studies, etc.). It also contributes to the networking of its members and develops the ecosystem's visibility, in order to boost market access.

Alsace BioValley relies on a dynamic network of French, German and Swiss companies to succeed, as well as leading academic and clinical research, and an integrated network of partners that are key players in innovation.

www.alsace-biovalley.com @AlsaceBiovalley



THE STEERING COMMITTEE

PHARMA, BIOTECH



Cédric Barrière
DIRECTOR, EXTERNAL INNOVATION
ONCOLOGY, EXTERNAL SCIENCE
AND PARTNERING, **SANOFI** (F)



Maria Bobadilla
SENIOR DIRECTOR, EXTENDING
INNOVATION NETWORK,
ROCHE (S)



Adrian Carter
CORPORATE VICE PRESIDENT AND
GLOBAL HEAD OF DISCOVERY
RESEARCH COORDINATION,
BOEHRINGER INGELHEIM (D)



Sami Chtourou
EXECUTIVE VICE PRESIDENT
INNOVATION & SCIENTIFIC
AFFAIRS, **LFB** (F)



Florence Dal Degan
R&D INNOVATION SOURCING
DIRECTOR, **NOVO NORDISK** (D)



Guy Hélin
CEO,
SYNGULON (F)



Stephan Lensky
CHIEF OPERATING AND CHIEF
BUSINESS OFFICE,
EPIMAB BIOTHERAPEUTICS (D)



Sabrina Lesage
STRATEGIC ALLIANCES MANAGER,
PFIZER (F)



Frédéric Scaërou
DIRECTOR, SCIENTIFIC
AFFAIRS ONCOLOGY,
IPSEN INNOVATION (F)



Nadine Weisslinger-Darmon
MEDICAL DIRECTOR SPECIALTY
PRODUCTS, CLINICAL RESEARCH AND
ACADEMIC ALLIANCES, **GSK** (F)

ACADEMIA, TTOs



Hervé Ansanay
OPERATIONS DIRECTOR,
SATT AXLR (F)



Jürgen Bauer
DEPUTY MANAGING DIRECTOR,
**EMBLEM TECHNOLOGY
TRANSFER** (D)



Garold Breit
DIRECTOR, TECHNOLOGY
BUSINESS DEVELOPMENT,
CITY OF CHARLESTON (US)



Nicolas Carboni
PRESIDENT,
SATT CONECTUS ALSACE (F)



Jean-Luc Chagnaud
HEALTHCARE BUSINESS
DEVELOPMENT MANAGER
& INTELLECTUAL PROPERTY
MANAGER, **AQUITAINE SCIENCE
TRANSFERT** (F)



Anthony Daccache
BUSINESS DEVELOPER,
SATT NORD (F)



Lilla Farkas
HEAD, OFFICE OF THE MANAGING
DIRECTOR, RESEARCH COORDINATOR,
**MPI-CBG, MAX PLANCK INSTITUTE
OF MOLECULAR CELL BIOLOGY
AND GENETICS** (D)



Esther Lange
INDUSTRY LIAISON MANAGER,
ASCENION (D)

INVESTORS



Franck Hensel
SENIOR INVESTMENT MANAGER,
HIGH-TECH GRÜNDERFONDS (D)



Sara Nunez-Garcia
BIOTECH INVESTOR, FORMERLY
PRINCIPAL WITH SOFINNOVA PARTNERS (F)



Lotfi Yelles Chaouche
PARTNER,
THEODORUS FUND (D)



Zhi Zhong Yao
ASSOCIATE, CAPITAL FUNDS,
SOFINNOVA PARTNERS (F)

ASSOCIATIONS, CLUSTERS & LAW FIRMS



Barbara Freischem
MANAGING DIRECTOR,
**EBE -EUROPEAN
BIOPHARMACEUTICAL ENTERPRISES** (D)




Yohan Grosjean
COMMUNICATION OFFICER,
**AFSSI - THE FRENCH ASSOCIATION
OF OUTSOURCING AND
INNOVATIVE COMPANIES** (F)



Jean-Louis Hunault
PRESIDENT, **SIMV - THE FRENCH
ASSOCIATION OF THE ANIMAL
HEALTH INDUSTRY** (F)



Marco Pintore
GENERAL MANAGER,
ALSACE BIOVALLEY (F)



Christian Policard
MEMBER OF THE BOARD,
CHAIRMAN OF THE BUSINESS
DEVELOPMENT SUB-COMMITTEE,
FRANCE BIOTECH (F)



Emilie Royère
DIRECTOR,
EUROBIOMED (F)



Cécile Théard-Jallu
PARTNER ATTORNEY, **DE GAULLE
FLEURANCE & ASSOCIÉS** (F)



Etienne Vervaecke
GENERAL MANAGER,
EURASANTE & NHL CLUSTER (F)

PARTNERING

*48 hours to meet your future project partners,
obtain funding and accelerate innovation*

IDENTIFY

today's innovative technologies, collaborations and licensing opportunities

BENEFIT

from a wide range of attendees (Pharma - Biotech - TTOs - Academics - Investors)

MEET

the most qualified players in the Life Sciences field

DEVELOP

new collaborations and partnerships

WHO WILL YOU MEET?



30% TTOs, Research institutions, Academics



20% Pharma & Diagnostic companies



20% Emerging Biotech companies



15% Preclinical CROs



10% Pre-seed, seed and Series A investors



5% Professional services, consulting and law firms

The partnering platform at BioFIT is powered by **partneringONE®**

a service of **EBD GROUP**

PRESENTATION SESSIONS

The early-stage innovations you need

The BioFIT presentation sessions offer the opportunity to detect the most innovative and promising start-ups, R&D projects and licensing opportunities in order to foster partnerships and business development in the Life Sciences field.

Start-up Slams

- The Start-up Slams are dedicated to **entrepreneurs** who have created an innovative company (< 5 years old or to be created).
- Selected applicants will have the opportunity to present their project in front of potential partners and investors during BioFIT.
- A jury composed of pharmaceutical experts and investors will give the presenters feedback and advice.
- The most innovative start-up will be given an award by BioFIT's jury.

Licensing Opportunity Presentations

- The Licensing Opportunity Presentations are dedicated to **TTOs, universities** or related structures that have **ready-to-be-licensed technologies**.
- The selected candidates will have the opportunity to present their out-licensing technologies in front of potential industry partners during BioFIT.



Apply
before 30th June
2018



Be selected
by a jury of
experts



Pitch
during BioFIT
2018

CONFERENCE PROGRAMME

TRACK 1 *Best practices in academia-industry R&D collaborations*

TRACK 2 *Nurturing and licensing early-stage assets*

TRACK 3 *Early-stage innovation: Identify the right funding sources*

PLENARY SESSION

4TH DEC. 11.30 AM - 1.00 PM

SEED FUNDS CROSSING BORDERS: HOW FAR AND HOW FAST IS THE EARLY-STAGE INVESTMENT MARKET IN BIOTECH GLOBALISING?

The globalisation of seed investment can be seen as traditionally geographically anchored, now early-stage investors tend to invest in more diverse areas. Where does the money come from? How far is this evolution towards more global funds going? How fast is it going in the investment community? Will it make the investors more willing to take risks, will it change the risk landscape? Isn't there an ill-balance today between the geographical origin of investment capabilities and the areas that are crawling with projects needing equity investment?

THE SPEAKERS

Over 70 international speakers will share their vision and experience. Among them:

Jan Adams,
Managing Director,
EMBL Ventures 🇪🇺

Anjan Aralihalli,
Venture Partner,
CTI Life Sciences Fund 🇮🇳

Caroline Barelle,
CEO,
Elasmogen 🇫🇷

Yann Barrault,
Head of Technology Transfer,
SATT Grand Centre 🇫🇷

Rodolphe Besserve,
Head SuFT Advisory,
Société Générale Corporate
Investments and Banking 🇫🇷

Marco A. Chacón,
Assistant Vice President of
Industry Alliances
University of Maryland,
Baltimore 🇺🇸

Alain Chevallier,
Life Sciences Partner,
Truffle Capital 🇫🇷

Madiha Derouazi,
Founder and CEO,
Amal Therapeutics 🇮🇳

Dean R. Edelman,
Corporate and Foundation
Relations,
Princeton University, Office
of the Dean for Research 🇺🇸

Lucie Ellis,
Senior Editor,
Script Intelligence 🇬🇧

Juan R. Garcia,
CEO and Founder,
BioSeed Capital 🇪🇸

Zishan Haroon,
Chairman & GP,
Julz Co 🇬🇧

George Hoffmann,
Co-founder and CEO,
Network Immunology 🇮🇳

Adrian Ibrahim,
Head of Business Development
and Technology Transfer,
Wellcome Trust Sanger
Institute 🇬🇧

Steven Klein,
VP Business Development,
IRICoR - Institute for Research in
Immunology and Cancer -
Commercialization of Research 🇮🇳

Gabor Lamm,
Managing Director,
Emblem Technology Transfer 🇪🇺

Peter Leonardi,
CEO,
Omnicyte 🇺🇸

Michael Motz,
Executive & Entrepreneur,
Netris Pharma 🇩🇪

Michael L. Salgaller,
Supervisor, Invention
Development & Marketing Unit,
Technology Transfer Center,
NIH 🇺🇸

Mirko Scherer,
Managing Partner and CEO,
TVM Capital China Limited 🇨🇳

Mathias Schmidt,
CEO,
Armagen Technologies 🇪🇺

Pascal Sempe,
Director Consultative Sales,
IBM 🇫🇷

Bernd Stowasser,
Head of Public Private
Partnerships - External
Innovation & Science Policy,
Sanofi 🇩🇪

Jonathan Tobin,
Investment Director,
Arix BioScience 🇬🇧

Ewa G. Truchanowicz,
Business Engagement
Manager, Alta Innovations 🇬🇧

Lisa Urquhart,
Editor,
EP Vantage 🇬🇧

Bram Vanparys,
Investment Director,
MS Ventures 🇮🇳

CONFERENCE PROGRAMME



TRACK 1

Best practices in academia-industry R&D collaborations

4TH DEC. 9.30 - 11.00 AM

ARTIFICIAL INTELLIGENCE TO SPEED UP DRUG DISCOVERY: THE REVOLUTIONARY ROAD TO ADVANCING INNOVATION

Companies are now using machine learning in highly specific ways to streamline and improve many day-to-day biomedical research tasks. The use of AI has shifted from generalist tasks to purpose-built tools with numerous applications to speed up drug discovery at all the different research stages. The panel will address some of the uses of AI, ultimately potentially cutting R&D costs by aggregating and synthesising information, repurposing existing drugs, generating and validating novel drug candidates, designing drugs and preclinical experiments, etc.

4TH DEC. 2.30 - 4.00 PM

BEYOND SHARED R&D MEANS, COMMON STRATEGIES FOR COLLECTIVE SUCCESS

Beyond sharing physical means, this session focuses on deliberate strategies of life sciences players and the academic world to pool R&D resources to address common questions and reach common goals through shared R&D strategies and aligned incentives. We will review some partnerships that have chosen to take a leap forward and collaborate together on scientific projects that they couldn't do on their own.

5TH DEC. 9.00 - 10.30 AM

A PROSPECTIVE OVERVIEW OF THE CROSS-INDUSTRY COLLABORATIONS AND LICENSING DEALS BETWEEN THE HUMAN AND ANIMAL HEALTHCARE INDUSTRIES

We will review potential partnerships that are prime examples of the collaborations that are occurring between the human and animal health drug development industries, to the benefit of all patients. Some of these research collaborations have led to forthcoming licensing agreements, and there is a strong belief that product development collaborations between the human and animal healthcare industries are key to meeting the unique challenges in both markets.

5TH DEC. 11.00 AM - 12.30 PM

PATIENT ORGANISATIONS TO JOIN THE PHARMA-BIOTECH-ACADEMIA TRIO: IS A FOURTH MUSKETEER CALLING FOR A NEW WAY TO MANAGE ALLIANCES?

What are the consequences and benefits of adding patient organisations to existing alliances? How do these collaborations work? How do they create value for the whole life sciences community? What is the actual influence on patients of public/private partnerships? What is the actual involvement of patient organisation in financing the collaborations?

CONFERENCE PROGRAMME



TRACK 2

Nurturing and licensing early-stage assets

4TH DEC. 2.30 - 4.00 PM

WHAT ARE THE RECENT INITIATIVES TO DE-RISK ASSETS OF ACADEMIC ORIGIN?

What are the latest group actions to have been jointly taken by the industry, academic institutions, equity investors and governmental bodies that take academic-origin assets as early as possible and inject the proper amount of money into them, in order to get the project licensed at the right moment and at the safest possible stage?

5TH DEC. 9.00 - 10.30 AM

WHAT IS THE RIGHT BALANCE BETWEEN EQUITY, ROYALTIES AND COLLABORATIVE RESEARCH INCOME FOR ACADEMIC INSTITUTIONS THAT ARE IN THE PROCESS OF SPINNING OUT COMPANIES?

When addressing the contractual relationships between a university and its spin-off: What are the issues as far as equity, royalties and research income are concerned? How do VCs, academic institutions, spin-off management and human resources management for the university interact? What are the main conflicts of interest that can arise from people holding dual positions, in the university and in the start-up? There are many different patterns among academic institutions and TTOs: Privileging short-term income through upfront payments, acting as a long-term partner through shareholder status in the spin-off. There is certainly not a single recipe for success...

5TH DEC. 2.00 - 3.30 PM

QUESTIONING TTO FINANCING MODELS: COULD THEIR EXPECTED FINANCIAL OUTCOME BIAS THE TECH TRANSFER PROCESS?

Many universities and countries have created tech transfer financing tools which aim at partly de-risking assets of academic origin. Should investors in those financing tools be the least demanding and the most patient to make such tech transfer tools succeed in the long run?

5TH DEC. 4.00 - 5.30 PM

UNDER PRESSURE: HOW DOES THE URGE TO BRING RARE DISEASE THERAPIES CREATE A NEW RANGE OF BUSINESS OR COLLABORATIVE MODELS?

Bringing new therapies to treat rare diseases requires more than scientific innovation. Innovation in business models and incubation financing is critical as the need to find ways to cost effectively develop new medication becomes increasingly important. Initiatives like collaboration centres and rare disease centres try to take the best of both worlds by implementing multidimensional approaches to address the needs of the rare disease community. In addition to conducting their own research, collaborative models that feature pharmaceutical companies, academic institutions, start-ups and patient groups are now being put in place.

CONFERENCE PROGRAMME



TRACK 3

Early-stage innovation: Identify the right funding sources

4TH DEC. 9.30 - 11.00 AM

AGNOSTIC OR PURE PLAYERS IN THE BIOTECH SECTOR: WHO IS BECOMING PROMINENT IN THE EARLY-STAGE FINANCING ROUNDS?

The seed investment market is comprised of players with a really varied degree of specialisation, from totally agnostic players involved in multiple industries, to pure players focusing on specific therapeutic areas. Do most specialised funds attract the more generalist types in the financing rounds? What is the importance of the amount of seed investment today for cross-industry funds, 100% healthcare-oriented funds and pure players in the biotech industry, respectively?

4TH DEC. 4.30 - 6.00 PM

SHAPING YOUR START-UP FOR AN INDUSTRIAL EXIT OR AN IPO: ARE THERE CHOICES TO BE MADE AT THE VERY INITIAL STAGE?

Decisions taken at the very initial stage have major consequences for the future development of start-ups with major pitfalls to be avoided. Is it crucial to picture the exit strategy as soon as the company has been created? The session relies on its panellists' stories to go over different approaches to IPO and exits for start-ups.

5TH DEC. 11.00 AM - 12.30 PM

ARE IMMUNOTHERAPIES A NEW INVESTMENT ELDORADO?

Investment in immunotherapy in 2018 is still attractive and sought out; what is its growth potential after several years of being an investment blockbuster? What have been the 2018 investment successes in immunotherapy? Will immunotherapy disrupt the oncology market? Are we at the growth, maturity, or saturation stage when we talk about investing in immunotherapy?



5TH DEC. 2.00 - 3.30 PM


HOW AVAILABLE TO BIOTECH START-UPS HAVE PHILANTHROPIC AND ALTERNATIVE SOURCES OF SOFT FUNDING BECOME TODAY?

All of these non-dilutive financing sources are becoming increasingly numerous thanks both to the emergence of interest expressed by many trusts and foundations in financing innovative start-ups and to the many governmental schemes that are devoted to financing the first steps of biotech start-ups. How do these sources of revenue lead to real leverage effect or create constraints for the companies? What types of constraints do they expose biotech entrepreneurs to?

DAY ONE

Tuesday 4th December

| | | | | | |
|----------------------|--|--|---|--|---------------------|
| 8.30 am 9.30 am | NAME BADGE PICKUP & WELCOME COFFEE | | | | |
| | Conferences and roundtable discussions | Presentation sessions | Hosted event  | Hosted event  | One-to-one meetings |
| 9.30 am 11.00 am | Agnostic or pure players in the biotech sector: Who is getting prominent in the early-stage financing rounds? | Artificial Intelligence to speed up drug discovery: The revolutionary road to advancing innovation | Licensing Opportunity Presentations | Insights from bariatric surgery Food and type 2 diabetes: Restoring the inside of the system | |
| 11.00 am 11.30 am | NETWORKING BREAK | | | EGID Poster Session | |
| 11.30 am 1.00 pm | PLENARY SESSION Seed funds crossing borders: How far and how fast is the early-stage investment market in Biotech globalising? | | | R&D dating for animal health and innovation | |
| 1.00 pm 2.30 pm | LUNCH | | | | |
| 2.30 pm 4.00 pm | Beyond shared R&D means, common strategies for collective success | What are the recent initiatives to de-risk academic-origin assets? | Start-up Slams | Incretins, diabetes and CV disease Gut-Brain glucose signaling in the control of energy homeostasis | |
| 4.00 pm 4.30 pm | NETWORKING BREAK | | | Award Ceremony of the AFVAC* | |
| 4.30 pm 6.00 pm | Shaping your start-up for an industrial exit or an IPO: Are there choices to be made at the very first stage? | Licensing Opportunity Presentations | Therapeutic potential of multi-incretin therapy — from mice to men Best paper award Conclusion & Invitation to the cheese and wine cocktail | R&D dating for animal health and innovation | |
| 6.30 pm | BIOPARTY | | | | |






POSTER AND
ORAL PRESENTATIONS
11th 2018 PRANCE

* AFVAC: French Association of Veterinarians for Pets

DAY TWO

Wednesday 5th December

| | | | | | | |
|----------------------|--|--|-------------------------------------|--|--|--|
| 8.30 am 9.00 am | WELCOME COFFEE | | | | | |
| | Conferences and roundtable discussions | | Presentation sessions | Hosted event  |  SIMV R&D DATING FOR ANIMAL HEALTH AND INNOVATION | |
| 9.00 am 10.30 am | What is the right balance of equity, royalties and collaborative research income for academic institutions in the process of spinning out companies? | A prospective overview of the cross-industry collaborations and licensing deals between the human and animal healthcare industries | Start-up Slams | | | |
| 10.30 am 11.00 am | NETWORKING BREAK | | | | | |
| 11.00 am 12.30 pm | Are immunotherapies a new investment Eldorado? | Patient organisations to join the pharma-biotech-academia trio: Is a fourth musketeer calling for a new way to manage alliances? | Licensing Opportunity Presentations | | | |
| 12.30 pm 2.00 pm | LUNCH + WBC Club: Would-be CEO Networking Lunch | | | | | |
| 2.00 pm 3.30 pm | How available to biotech start-ups have philanthropic and alternative sources of soft funding become today? | Questioning TTO financing models: Could their expected financial outcome bias the tech transfer process? | Start-up Slams | R&D dating for animal health and innovation |  Biofit NUTRITION & WELLNESS JULY 2018 - FRANCE | |
| 3.30 pm 4.00 pm | NETWORKING BREAK | | Start-up Slams Award Ceremony | | | |
| 4.00 pm 5.30 pm | Under pressure: How does the urge to bring rare disease therapies create a new range of business or collaborative models? | | | | | |

One-to-one meetings



TRACK 1
Best practices in academia-industry R&D collaborations



TRACK 2:
Nurturing and licensing early-stage assets



TRACK 3:
Early-stage innovation: Identify the right funding sources

R&D DATING FOR ANIMAL HEALTH AND INNOVATION



BioFIT 2018 will host the 4th edition of the “R&D dating for Animal Health and Innovation” business convention, at the French association for the animal healthcare industry (SIMV)’s initiative, on the 4th and 5th of December 2018, in Lille.

Today, public-private and private-private partnerships are thought to be the leverage that is needed for innovation. That is why the SIMV launched the “R&D dating for Animal Health and Innovation”, which strives to initiate high-level exchanges between research departments of the veterinary medicine and diagnostics industry and public research, as well as with biotechnology companies (start-ups).

By enabling face-to-face encounters, the event will enhance the visibility of cutting-edge research in France and in Europe, encourage investments and lead to therapeutic innovation.

Contact: secretariat@simv.org

Organised by:



EGID SYMPOSIUM



4th December 2018 | Lille

5th edition:
THE GUT, INCRETINS, DIABETES

Steering Committee



**Philippe
Froguel**

MD, Ph D, Director of UMR CNRS 8199-University of Lille and Pasteur Institute of Lille, Director of Research Federation 3508 labex EGID and Director of equipex LIGAN Personalized Medicine and Institute of Genomics of Lille



**François
Pattou**

Professor of surgery, University of Lille, CHU Lille Inserm



**Bart
Staels**

Director of UMR1011 Inserm, University of Lille – EGID, CHU Lille, Pasteur Institute of Lille

Programme Overview

Insights from bariatric surgery

Rachel Batterham, Professor of Obesity, Diabetes and Endocrinology – NIHR Research Professor, Head of UCLH Obesity & Bariatric Services, Head of Center for Obesity Research, Department of Medicine, Rayne Building, University College London

Food and type 2 diabetes: Restoring the inside of the system

Roy Taylor, Professor of Medicine and Metabolism, Magnetic Resonance Centre, Campus for Ageing and Vitality, Newcastle upon Tyne

Incretins, diabetes and CV disease

Nikolaus Marx, Director of the Medical Cardiology Clinic – Cardiology, pulmonology, angiology, internal intensive care Aachen University Hospital

Gut-Brain glucose signaling in the control of energy homeostasis

Gilles Mithieux, Research Director – CNRS Director of U1213, Nutrition, Diabetes and the Brain

Therapeutic potential of multi-incretin therapy –from mice to men

Aimo Kannt, Head of Department, General Metabolism & Obesity, Sanofi

In partnership with:



WOULD-BE CEO NETWORKING LUNCH

BioFIT and the WBC Incubator are pleased to announce that they will be putting together a special edition of WBC Club during BioFIT 2018 in Lille. This session, called «Would-be CEO Networking Lunch», will be held on the second day of BioFIT (5th December).

As talented CEOs are so much sought-after by so many stakeholders of the biotech industry, to both launch and drive new companies to success, this special WBC Club session will bring together representatives of emerging start-ups, technology transfer offices, incubators and investing networks as well as CEOs and would-be CEOs to address this crucial issue.

Since 2010, WBC Incubator has validated close to 100 biotech professionals in Belgium for their ability to match and work with scientific founders and entrepreneurs with the collective aim to build together more exciting business plans, stronger investment propositions and faster business development programmes. In Belgium, biotech CEOs and Would-be CEOs meet regularly to discuss business opportunities during so-called WBC Club events.

The «Would-be CEO Networking Lunch» is organised to present the WBC incubation model to BioFIT participants. Please also note that Would-be CEOs will be identified using the BioFIT partnering platform.

Any bioentrepreneur looking for a project to get involved in is welcome to join BioFIT and particularly this would-be CEOs networking lunch. Any incubator or tech transfer entity looking for an entrepreneur to lead their start-up launch projects is also welcome to join.

Organised by:



IMODE

IMODE is organising its second annual convention during BioFIT with a morning of conferences and participation in the BioFIT one-to-one meetings during the afternoon.

4TH DEC. 9.30 AM - 1.00 PM

A conference that will feature an introduction presenting IMODE and its research updates, and then guests talks on the following subjects:

- Electrospinning approach to drug delivery;
- Regenerative medicine approach;
- Functionalised nanoparticles approach;
- Tissue Engineering approach;
- Cardiovascular disease, Restenosis and Thrombosis.

IMODE is a collaborative research project for multicomponent pharmaceutical products (co-amorphous and co-crystals) and medical devices that are loaded with bioactive molecules. Started in 2016, the IMODE project is funded by the European Interreg 2 Seas programme and co-financed by the European Fund for Regional Development (EFRD).

The project's overall objective is to bring together the specific transdisciplinary skills and experiences of partners (academic research groups, development agencies, SMEs) in order to provide the 2 Seas Area with strategic advantages for innovative pharmaceutical and medical applications. The IMODE project is motivated by an unmet need to develop solutions to addressing societal challenges to improve healthcare and provide novel and effective medication for various cardiovascular or gastro-intestinal conditions that lack or have inadequate treatment, all while keeping medical costs low.

Organised by:



Project partners:





The leading European
partnering event for
early-stage innovations
and seed investment
in the Life Sciences field

REGISTER NOW FOR BIOFIT 2018

REGISTRATION FEES

(excl. VAT)

Mature company (> 5 years old)

Investor (pre-seed, seed or Series A)

Cluster | Association

TTO | Research institution

Emerging company (≤ 5 years old)
or SME (≤ 5 employees)

Academic scientist

| | EARLY BIRD before 30 th June included | REGULAR FEE from 1 st July until 4 th November included | LATE REGISTRATION from 5 th November |
|--|--|---|---|
| Mature company (> 5 years old) | € 959 | € 1,199 | € 1,319 |
| Investor (pre-seed, seed or Series A) | € 959 | € 1,199 | € 1,319 |
| Cluster Association | € 816 | € 1,019 | € 1,121 |
| TTO Research institution | € 639 | € 799 | € 879 |
| Emerging company (≤ 5 years old) or SME (≤ 5 employees) | € 384 | € 479 | € 527 |
| Academic scientist | € 319 | € 399 | € 439 |

EXHIBITION FEES (excl. VAT)

Gain visibility by exhibiting at a fully equipped booth within the exhibition area and have your one-to-one meetings at your own stand:

- 6 m² equipped booth - € 2,200 (1 partnering pass included)
- 9 m² equipped booth - € 3,300 (1 partnering pass included)
- 12 m² equipped booth - € 4,400 (1 partnering pass included)
- 18 m² equipped booth - € 6,600 (2 partnering passes included)

SPONSORSHIP OPPORTUNITIES (excl. VAT)

Discover the sponsorship opportunities and maximise your presence:



Gold Sponsor
€ 15,000



Silver Sponsor
€ 10,500



Bronze Sponsor
€ 6,000

There are many additional
visibility opportunities, please
contact us for a customised
offer.

EVENT VENUE

Lille Grand Palais
1, boulevard des Cités Unies
59000 Lille - France

www.biofit-event.com

 **@BIOFIT_EVENT**

CONTACTS

GENERAL ENQUIRIES:

Margaux Satola
msatola@eurasante.com
+33 (0)3 59 39 01 82

CONFERENCE PROGRAMME:

Ramona Pirv
rpirv@eurasante.com
+33 (0)3 59 39 01 84

LILLE AND THE HAUTS-DE-FRANCE REGION, A REGION OF EXCELLENCE IN THE HEALTHCARE SECTOR

The Lille Region is the 3rd ranked life sciences cluster in France. The main areas of expertise in the Hauts-de-France region are metabolic diseases, ageing diseases, nutrition and blood related products. The pharma-biotech sector in Northern France enjoys the presence of both big companies (AstraZeneca, Bayer, GSK...), a dense network of innovative start-ups (AlzProtect, ImaBiotech, Innobiochips...) and dynamic mid-size biopharmaceutical companies (Diagast, Genfit, Genoscreen, LFB...).

The Pharma-Biotech sector in the Hauts-de-France region:

- Export turnover of more than €3 billion
- Regional turnover of €6 billion (11% of the €53 billion national turnover)
- 11,600 jobs (11% of jobs in France in this sector)



Organised by:



In collaboration with:



Institutional partners:

